Halberd Corporation (HALB)
OTC PINK OTC PINK Primary 
Halberd Corporation Continues Seeking Government Contracts with Scientists at Mississippi State University
Key Takeaways Jackson Center, PA, November 3, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) – Halberd Corporation (OTC: HALB), through its collaboration with scientists at Mississippi State University, continues work on a planned fourth quarter submission to the United States government seeking contractual funding for advanced animal research for the development
Halberd Corporation Acquires NeuroSense AI Corp., a Revolutionary Behavioral Intelligence Platform to Transform TBI, Other Research, and Clinical Assessment
First-of-its-Kind Multi-Modal AI Platform Combines Advanced Behavioral Analysis with Claude AI to Accelerate Traumatic Brain Injury Recovery Monitoring, Among Other Medical Applications Jackson Center, PA, September 29, 2025 – PRISM MediaWire (Press Release Service – Press Release Distribution) Halberd Corporation (OTC: HALB) today announced its acquisition of NeuroSense AI Corp.
Halberd, Athena GTX, Inc. & Athena Telemedicine Partnership, LLC Clinical Study Updates
Issues nationwide nephrologist solicitation for patients for a 100-patient study involving kidney disease JACKSON CENTER, Pa.
Progress Update on Halberd, Athena GTX and Athena Telemedicine Partnership, LLC Joint Projects
The US Government Granted Athena GTX a $2,866,000 Final Development Contract Award! Key Points: Athena GTX has been awarded a $2,866,000 final development contract from the U.S. government for its Smart Autonomous Critical Care System (S-ACCS).
Halberd Update on WatchDawg® PTSD Treatment
Next Phase Pilot Study Jackson Center, PA, December 2, 2024 – PRISM MediaWire – Halberd Corporation (OTC PINK: HALB) previously reported results of a recently concluded initial 10-person Pilot Study of volunteer veterans suffering from PTSD and possible suicidal ideation. The results of that study can be found here.
Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study
Ten Military Veteran Volunteers Participated in the Pilot Study Enabled by Athena GTX Health Monitoring System Jackson Center, PA, October 1, 2024 – PRISM MediaWire – Halberd Corporation (OTC PINK: HALB) released the results of the recently completed WatchDawg® Pilot Study.
Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD
Contributing Funding and a Significant Additional Tool to Combat PTSD and TBI Jackson Center, PA., September 11, 2024 – PRISM MediaWire – Halberd Corporation (OTC PINK: HALB), in coordination with Athena Telemedicine Partners (ATP) and Athena GTX, Inc., is pleased to announce a substantial contract award commitment.
Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
Early Pilot Study Data from Veteran Volunteers is Compelling – Part B Jackson Center, PA September 9, 2024 – PRISM MediaWire – Halberd Corporation (OTC: HALB) today issued the following letter to its shareholders: We hope you have had an opportunity to check out last week's Press release, Part A.
Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction
Early Pilot Study Data from Veteran Volunteers is Compelling Jackson Center, PA September 4, 2024 – PRISM MediaWire – Halberd Corporation (OTC: HALB) To our shareholders: As promised, this is the second of three Press Releases on our recent progress.
Halberd Corp. Issues Letter to Shareholders
JACKSON CENTER, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) — Halberd Corporation (OTC PINK: HALB) today issued the following letter to its shareholders: Halberd Corp.
Halberd Corp's (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results
Jackson Center, PA July 24, 2024 – Halberd Corporation (OTC-PINK: “HALB”) has announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-AxTM nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma. Dr.
